EU experts weigh up medical DEHP risks

Policymakers should consider the potential for replacing the phthalate DEHP in medical devices but must weigh up factors including its usefulness in treatment, experts told the European Commission

Policymakers should consider the potential for replacing the phthalate DEHP in medical devices but must weigh up its usefulness in treatment and the drawbacks of alternative substances, experts have advised the European Commission.

The Scientific Committee on Emerging and Newly-Identified Health Risks said that premature babies “represent a high-risk population to DEHP exposure”, while patients undergoing haemodialysis may receive more than the tolerable daily intake (TDI) and “are at risk of DEHP-induced effects”.

Please sign in to access this article. To subscribe, view our subscription options, or take out a free trial.

Please enter your details

Forgotten password?

Having trouble signing in?

Contact Customer Support at
subs@endseurope.com
or call 020 8267 8120

Not a subscriber?

Take a free trial now to discover the critical insights and updates our coverage offers subscribers.